Trial completion date • Trial primary completion date • Combination therapy
|
ALK (Anaplastic lymphoma kinase) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1) • BCL6 (B-cell CLL/lymphoma 6)
|
ALK positive • BCL2 expression • MYC expression • CD20 expression • BCL6 rearrangement • BCL2 rearrangement
|
Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • Calquence (acalabrutinib) • vincristine